RXi Pharmaceuticals Corporation, a biotech company focused on discovering and developing therapies primarily in the areas of dermatology and ophthalmology, has been granted by the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its second clinical candidate, Samcyprone, for the treatment of malignant melanoma stage IIb to IV. A number of patients with stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone is being developed for treatment of these metastas...